|Home||Log In||Register||Our Services||My Account||Contact||Help|
|Stockwatch||Level 2||Portfolio||Charts||Share Price||Awards||Market Scan||Videos||Broker Notes||Director Deals||Traders' Room|
|Funds||Trades||Terminal||Alerts||Heatmaps||News||Indices||Forward Diary||Forex Prices||Shares Magazine||Investors' Room|
|CFDs||Shares||SIPPs||ISAs||Forex||ETFs||Comparison Tables||Spread Betting|
The evening exposes investors to companies across various sectors. Perfect for existing investors as well as those looking for new investment opportunities.
Wednesday 12 September 2018Venue:
Radisson Blu Hotel Edinburgh, 80 High Street, The Royal Mile, Edinburgh, EH11THEvent Timings:
Registration and coffee
• Dr. Mark Payton, CEO - Mercia Technologies (MERC)
• Malcolm Groat, FD - Tekcapital (TEK)
• Michael Billing, Executive Chairman & CEO - Thor Mining (THR)
Drinks reception and canapés
Mercia is a national investment group focused on the funding and scaling of innovative technology businesses with high growth potential from the UK regions. Mercia benefits from 19 university partnerships and offices across the Midlands, the North of England and Scotland providing it with access to high quality, regional deal flow. Mercia Technologies PLC is quoted on AIM with the epic "MERC".
Mercia's 'Complete Capital Solution' initially nurtures businesses via its third party funds (now with circa £350.0million under management following recent mandate wins) and then over time Mercia can provide further funding to its 'Emerging Stars' by deploying direct investment follow-on capital from its own balance sheet. Since its IPO in December 2014, Mercia has invested over £46.0million directly across its portfolio of 'Emerging Stars'.
SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.
The SkinBioTherapeutics’ platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, improve repair and reduce bacterial load.
SkinBioTherapeutics is targeting three specific skin healthcare sectors; cosmetics, infection control and eczema. In each of these areas SkinBioTherapeutics plans to exemplify its technology in human studies. The most advanced programme is focused on the application of the Skinbiotix® platform in managing sensitive skin in the cosmetics industry. The business strategy is to partner and outlicense its programmes at proof of concept.
Tekcapital plc is a UK IP investment group focused on creating market value from university technology. We accomplish this by acquiring, enhancing and developing bright new discoveries from our network of over 4,500 universities and research centres in 160 countries. We also provide a suite of bespoke tech transfer services to accelerate commercialisation of university innovations.
Thor Mining is a resources company quoted on the AIM Market and on ASX in Australia. Thor holds 100% of the advanced Molyhil tungsten project in the Northern Territory of Australia, for which an updated feasibility study in 2015 suggested attractive returns. Thor also holds 100% of the Pilot Mountain tungsten project in Nevada USA which has a JORC 2012 Indicated Resources Estimate on one of the four known deposits. Thor is also acquiring up to a 60% interest in Australian copper development company Environmental Copper Recovery SA Pty Ltd, which in turn holds rights to earn up to a 75% interest in the mineral rights and claims over the portion of the historic Kapunda copper mine in South Australia recoverable by way of in-situ recovery.
Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
As cancer screening programs become more widespread, Volition's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.